Inclusion Criteria:

• * Written informed consent from parent/guardian before any study-specific procedures are performed, if applicable per local regulations.
• * Age-appropriate assent or informed consent from subject before any study-specific procedures are performed.
• * Subjects who have completed 24 weeks of treatment with study drug (voclosporin/placebo) in the VOCAL study. Subjects who had a temporary interruption and were able to successfully re-start study drug will be allowed to enroll after Medical Monitor approval.
• * In the opinion of the Investigator subject requires continued immunosuppressive therapy.
• * Subject is willing to continue to take oral MMF for the duration of the study.

Exclusion Criteria:

• * Currently taking or known need for any of the following medications during the study:
• * Cholestyramine or other drugs that may interfere with enterohepatic recirculation of MMF
• * Calcineurin inhibitors (CNIs) (e.g., cyclosporin and tacrolimus)
• * Strong CYP3A4/5 inhibitors and inducers (e.g., ketoconazole, rifampin, itraconazole, clarithromycin)
• * Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
• * A planned kidney transplant within study treatment period.
• * Subjects with any medical condition which in the Investigator's judgement may be associated with increased risk to the subject or may interfere with study assessments or outcomes